argenx SE (ARGX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Amsterdam, Netherlands. 현재 CEO는 Timothy Van Hauwermeiren.
ARGX 을(를) 보유 IPO 날짜 2017-05-18, 1,599 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $51.26B.
Argenx SE is a biotechnology company headquartered in Amsterdam, Netherlands, focused on developing innovative therapies for autoimmune diseases across the United States, Europe, Japan, China, and other global markets. The company's lead product, efgartigimod, targets multiple autoimmune conditions including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris, with a pipeline of additional candidates such as empasiprubart and ARGX-119 addressing conditions like motor neuropathy and amyotrophic lateral sclerosis. Argenx has established strategic partnerships with major pharmaceutical companies including AbbVie, Zai Lab, and LEO Pharma, along with collaborations with leading academic institutions and biotech firms to advance its research and development efforts. The company leverages proprietary platforms and technologies, including its SIMPLE ANTIBODY technology, to discover and develop novel therapeutic antibodies with applications in immunology and oncology.
